Article
Silibinin and its 2,3‐dehydro‐derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation
9 Dec 2014
Abstract excerpt
Basal cell carcinoma (BCC) is the most common cancer worldwide, and its current treatment options are insufficient and toxic. Surprisingly, unlike several other malignancies, chemopreventive efforts against BCC are almost lacking. Silibinin, a natural agent from milk thistle seeds, has shown strong efficacy against several cancers including ultraviolet radiation-induced skin (squamous) cancer; however, its...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
